{"nctId":"NCT02370251","briefTitle":"Compassionate Use of Omegaven in Children","startDateStruct":{"date":"2015-06","type":"ACTUAL"},"conditions":["Total Parenteral Nutrition-induced Cholestasis","Cholestasis","Short Bowel Syndrome","Gastroschisis","Intestinal Atresia","Infant, Premature, Diseases","Cholestasis of Parenteral Nutrition"],"count":63,"armGroups":[{"label":"Omegaven","type":"EXPERIMENTAL","interventionNames":["Drug: Omegaven"]}],"interventions":[{"name":"Omegaven","otherNames":["Fish oil-based lipid","Omega-3-fatty acid lipid emulsion"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Live in or temporarily relocate to Oklahoma\n* Age less than 18 years, both sexes, all races\n* Have a direct bilirubin level of â‰¥2 mg/dL for two consecutive weeks after at least 14 days of parenteral nutrition\n* Received parenteral lipids at a maximum dose of 1.7 g/kg/day (24 g/kg over the two weeks prior)\n* Are not currently enrolled in another lipid emulsion study\n\nExclusion Criteria:\n\n* Known food allergy to fish\n* Known metabolic disorder of lipid metabolism\n* Active coagulopathies (active bleeding or requiring blood product treatment in the prior 48 hours)\n* Medical condition likely to result in death in the next 30 days","healthyVolunteers":false,"sex":"ALL","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Resolution of Cholestasis for Subjects Who Received Omegaven","description":"To determine if Omegaven results in the resolution of cholestasis (DB \\<2 for 2 consecutive weeks)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Issues for Infants Who Received Omegaven","description":"To determine if Omegaven results in safety issues such as increased bleeding, essential fatty acid deficiency, elevated liver function tests, increased liver and/or intestinal transplant rates, or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Essential Fatty Acid Deficiency in Infants Who Received Omegaven","description":"To determine if Omegaven can resolve essential fatty acid deficiency","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":52},"commonTop":[]}}}